Results 31 to 40 of about 156,654 (268)

Ginsenosides: Allies of gastrointestinal tumor immunotherapy

Frontiers in Pharmacology, 2022
In the past decade, immunotherapy has been the most promising treatment for gastrointestinal tumors. But the low response rate and drug resistance remain major concerns.
Yutao Feng, Fen Ma, Enjiang Wu, Zewei Cheng, Zhengtao Wang, Li Yang, Jiwei Zhang   +6 more
doaj   +1 more source

Active immunotherapy options for Alzheimer’s disease [PDF]

Alzheimer's Research & Therapy, 2014
Alzheimer's disease (AD) is the most common cause of dementia and a major contributor to disability and dependency among older people. AD pathogenesis is associated with the accumulation of amyloid-beta protein (Aβ) and/or hyperphosphorylated tau protein in the brain. At present, current therapies provide temporary symptomatic benefit, but do not treat
Winblad, Bengt, Graf, Ana, Riviere, Marie-Emmanuelle, Andreasen, Niels, Ryan, J   +4 more
openaire   +2 more sources

Cellular and vaccine therapeutic approaches for gliomas

Journal of Translational Medicine, 2010
Despite new additions to the standard of care therapy for high grade primary malignant brain tumors, the prognosis for patients with this disease is still poor.
Liau Linda M, Prins Robert M, Jadus Martin R, Erickson Kate L, Malone Colin C, Hickey Michelle J, Kruse Carol A   +6 more
doaj   +1 more source

Active ingredients of traditional Chinese medicine for enhancing the effect of tumor immunotherapy

Frontiers in Immunology, 2023
Immunotherapy is a type of treatment that uses our own immune system to fight cancer. Studies have shown that traditional Chinese medicine (TCM) has antitumor activity and can enhance host immunity. This article briefly describes the immunomodulatory and
Chao Yang, Dan Li, Chung-Nga Ko, Kai Wang, Haiyong Wang   +4 more
doaj   +1 more source

Association Between Dinutuximab Beta Exposure and Post‐End‐of‐Treatment Survival in Neuroblastoma: A Weighted Patient‐Level Analysis of Three Clinical Studies

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Objectives The association between exposure to dinutuximab beta (DB) and event‐free survival (EFS) or overall survival (OS) of neuroblastoma patients was assessed using data collected during three clinical trials (five cohorts). Methods A systematic review (March 2026) was conducted to identify relevant studies (prospective; registered DB ...
Przemysław Holko, Holger N. Lode, Alberto Garaventa, Carla Manzitti, Roberto Luksch, Dominique Valteau‐Couanet, Marion Gambart, John Anderson, Juliet Gray, Adela Canete, Lucas Moreno, Aleksandra Wieczorek, Cormac Owens, Shifra Ash, Isaac Yaniv, Genevieve Laureys, Hans Loibner, Katarzyna Śladowska, Ruth Ladenstein, Paweł Kawalec   +19 more
wiley   +1 more source

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0

Journal for ImmunoTherapy of Cancer, 2023
Since the first approval for immune checkpoint inhibitors (ICIs) for the treatment of cutaneous melanoma more than a decade ago, immunotherapy has completely transformed the treatment landscape of this chemotherapy-resistant disease. Combination regimens
Omid Hamid, Diwakar Davar, Keisuke Shirai, Benjamin Izar, Charlotte E Ariyan, Michael K Wong, Jason J Luke, Janis M Taube, Anna C Pavlick, Meghan J Mooradian, Douglas B Johnson, Hussein A Tawbi, Tara C Mitchell, Ryan J Sullivan, April KS Salama, Krista M Rubin, Elizabeth I Buchbinder, Sarah A Weiss, Tina J Hieken, Geoffrey T Gibney, Rajan P Kulkarni, J Keith Tolley, Caressa Valdueza   +22 more
doaj   +1 more source

Phase Angle as an Early Functional Biomarker of Cancer‐Related Fatigue in Pediatric Oncology: A Prospective Longitudinal Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Pediatric cancer remains a leading cause of morbidity and mortality worldwide, particularly in low‐and middle‐income countries. Cancer treatment may impair nutritional status, alter body composition, and exacerbate cancer‐related fatigue (CRF).
Luís Carlos Lopes‐Junior, Luiz Claudio Barreto Silva Neto, Fabiano Kenji Haraguchi, Letícia Batista de Azevedo, Marcelo Brenner Nascimento Carlini, Raphael Manhães Pessanha, Mariana Rabello Laignier, Wesley Rocha Grippa, Tania Mara Lopes Bitti Bortolini, Gláucia Zouain‐Figueiredo, Regina Aparecida Garcia de Lima, Liliana Vasquez   +11 more
wiley   +1 more source

Immunotherapy in hematologic malignancies: past, present, and future

Journal of Hematology & Oncology, 2017
The field of immunotherapy in cancer treatments has been accelerating over recent years and has entered the forefront as a leading area of ongoing research and promising therapies that have changed the treatment landscape for a variety of solid ...
Annie Im, Steven Z. Pavletic
doaj   +1 more source

Active immunotherapy in treatment of acute leukaemia [PDF]

BMJ, 1969
Active non-specific immunotherapy has been used to prolong remissions in acute lymphoblastic leukaemia. The series reported here used Bordetella pertussis vaccine in a controlle trial after intensive chemotherapy. Possibly immunotherapy delayed the onset of relapse in the treated patients, but no long-term remissions were obtained.
R J, Guyer, D, Crowther
openaire   +2 more sources

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source